Questions & explanations
1. A patient has a single episode of brainstem symptoms and MRI shows one brainstem lesion. CSF shows oligoclonal bands. Does this meet McDonald criteria?
Yes, this can meet McDonald criteria for MS. The single clinical attack (brainstem) is a typical MS syndrome. MRI shows dissemination in space (one brainstem lesion counts as one area; need at least two areas—but if the lesion is in brainstem, that's one area; you need another area like periventricular or spinal cord. However, if only one lesion, DIS is not met. But if OCBs are positive, they can substitute for DIT. But DIS still requires lesions in ≥2 areas. So if only one lesion, criteria not fully met. The question likely implies additional lesions? Actually, the scenario may be incomplete. Typically, a single attack with OCBs and MRI showing DIS (≥2 areas) allows diagnosis. So if the MRI shows only one lesion, DIS is not met. So answer: Not enough for MS diagnosis; need more lesions or second attack.
2. How does the approach to symptom management differ in progressive MS compared to relapsing MS?
In progressive MS, symptom management focuses more on rehabilitation (physical therapy, occupational therapy) and assistive devices (canes, walkers, wheelchairs) to maintain function and quality of life. Because disease-modifying therapies have limited effect, managing symptoms like spasticity (muscle stiffness), fatigue, bladder problems, and pain becomes central. Medications for spasticity include baclofen and tizanidine; for fatigue, modafinil or amantadine may be used. In relapsing MS, the priority is to stop relapses with DMTs and treat acute attacks with steroids. In progressive MS, the goal shifts to slowing disability and maximizing independence through multidisciplinary care (involving neurologists, physiatrists, and therapists).
3. What are monogenic disorders that cause stroke?
Monogenic disorders are single-gene mutations that directly increase stroke risk. Examples include CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), caused by NOTCH3 gene mutations, leading to recurrent small vessel strokes and dementia. Fabry disease, an X-linked disorder, causes stroke due to enzyme deficiency and accumulation of globotriaosylceramide in blood vessels. Other disorders include MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) and hereditary hemorrhagic telangiectasia (HHT), which causes arteriovenous malformations. These disorders often present with stroke at a young age or with a family history. Genetic testing can confirm the diagnosis.
4. How do polygenic risk factors contribute to stroke?
Polygenic risk refers to the combined effect of many common genetic variants, each with a small effect, that increase stroke susceptibility. These variants are identified through genome-wide association studies (GWAS). They influence pathways like blood pressure regulation, lipid metabolism, inflammation, and coagulation. For example, variants in the PITX2 gene are linked to atrial fibrillation, a major cause of cardioembolic stroke. Polygenic risk scores (PRS) sum the effects of multiple variants to estimate an individual's genetic risk. However, PRS alone is not a strong predictor; it interacts with lifestyle and environmental factors. Understanding polygenic risk can help identify high-risk individuals for targeted prevention.
5. What unique challenges exist in managing MS in children compared to adults?
Managing MS in children presents unique challenges. First, the impact on school performance and social development is a major concern, as cognitive issues can affect learning. Second, treatment adherence (taking medication as prescribed) can be difficult due to side effects or the need for injections. Third, the long-term safety of DMTs is less well-known in children, as most drugs are studied in adults. Fourth, growth and puberty can affect drug dosing and metabolism. Finally, children may need additional support from a multidisciplinary team including pediatric neurologists, psychologists, and school counselors. Vaccination schedules also need to be carefully planned, especially before starting immunosuppressive therapies.
6. Why is treating progressive MS more challenging than treating relapsing MS?
Treating progressive MS is more challenging because the disease mechanisms are different. In relapsing MS, inflammation (immune attack) is the main driver, and anti-inflammatory drugs work well. In progressive MS, there is also neurodegeneration (nerve cell death) and chronic inflammation behind a closed blood-brain barrier (the protective lining of brain blood vessels), which are harder to stop. Many drugs that work for relapsing MS have not shown benefit in progressive forms. Additionally, disability in progressive MS is often due to accumulated damage, which may be irreversible. Clinical trials in progressive MS take longer because the primary goal is to slow disability worsening, which is measured over months to years.
7. What is a BTK inhibitor and how does it work in MS?
A BTK inhibitor is a type of drug that blocks Bruton's tyrosine kinase (BTK), an enzyme (a protein that speeds up chemical reactions) important for the activation and survival of B cells (immune cells) and microglia (immune cells in the brain). By inhibiting BTK, these drugs reduce the activity of B cells, which are involved in the immune attack on myelin in MS. They also may reduce inflammation in the brain by targeting microglia. Examples include evobrutinib and tolebrutinib, which are still being studied in clinical trials (research studies in people). Early results show they can reduce new MRI lesions and relapses. They are taken orally (by mouth) and may have a different safety profile compared to other MS therapies.
8. How does cerebral small vessel disease contribute to stroke?
Small vessel disease (SVD) causes stroke through two main mechanisms: lacunar infarcts and intracerebral hemorrhage. Lacunar infarcts result from occlusion of small penetrating arteries, leading to small deep infarcts. SVD also weakens vessel walls, causing microbleeds and larger hemorrhages, especially in cerebral amyloid angiopathy. Additionally, SVD impairs the blood-brain barrier and causes chronic hypoperfusion, leading to white matter damage and increasing the risk of both ischemic and hemorrhagic stroke. The presence of SVD on imaging is a marker of increased stroke risk and poor outcome after stroke. Treatment focuses on blood pressure control and antiplatelet therapy for ischemic stroke prevention.
9. What is the management of intracerebral hemorrhage due to cerebral amyloid angiopathy?
Management of CAA-related ICH focuses on acute care and preventing recurrence. Acute treatment includes blood pressure control, reversal of anticoagulation if present, and surgical evacuation for large life-threatening hemorrhages. For prevention, strict blood pressure control is key. Anticoagulants and antiplatelets are generally avoided because they increase bleeding risk. If anticoagulation is needed (e.g., for atrial fibrillation), the risk of recurrent ICH must be weighed against the risk of ischemic stroke. Some studies suggest that direct oral anticoagulants may be safer than warfarin. There is no specific therapy to remove amyloid deposits. Recurrent hemorrhages are common, and prognosis is guarded.
10. What is alemtuzumab and why is it used with caution in MS?
Alemtuzumab is a monoclonal antibody that targets CD52, a protein on the surface of mature immune cells (lymphocytes). It causes a long-lasting depletion of these cells, followed by a slow repopulation (re-growth) that resets the immune system. It is very effective for relapsing MS but is used with caution because of serious side effects. These include autoimmune conditions (where the immune system attacks the body) like thyroid disease (overactive or underactive thyroid), immune thrombocytopenia (low platelets causing bleeding), and kidney problems. It also increases the risk of infections. Because of these risks, alemtuzumab is usually reserved for patients who have not responded well to other therapies.
11. How do monogenic and polygenic factors differ in their impact on stroke?
Monogenic disorders have a large effect on stroke risk and often cause stroke at a young age, with a clear family history. They are rare but have a high penetrance, meaning most carriers develop the condition. Polygenic factors are common but each variant has a small effect; they contribute to the overall population risk. Monogenic disorders often involve specific mechanisms like vascular wall abnormalities (CADASIL) or enzyme deficiencies (Fabry), while polygenic factors influence common risk factors like hypertension and atrial fibrillation. Treatment for monogenic disorders may be specific (e.g., enzyme replacement for Fabry), whereas polygenic risk is managed by controlling traditional risk factors.
12. What is the main difference between fingolimod and siponimod in terms of receptor selectivity?
Fingolimod is a non-selective S1P receptor modulator, meaning it binds to several types of S1P receptors (subtypes 1, 3, 4, and 5). This broad binding is thought to contribute to its side effects, such as slow heart rate (bradycardia) and increased risk of infections. Siponimod is more selective, binding mainly to S1P receptor subtypes 1 and 5. This selectivity may reduce some side effects, particularly the heart rate slowing, and allows for a faster dose escalation (starting with a low dose and increasing gradually) without the need for first-dose observation in some patients. Siponimod is also approved for secondary progressive MS (a form that follows relapsing-remitting MS with worsening disability).